SINONASAL ADENOID CYSTIC CARCINOMA
Clinical trials for SINONASAL ADENOID CYSTIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new SINONASAL ADENOID CYSTIC CARCINOMA trials appear
Sign up with your email to follow new studies for SINONASAL ADENOID CYSTIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to make inoperable sinus cancer removable
Disease control Recruiting nowThis phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted antibody-drug conjugate) and epirubicin (a standard chemo)—in 40 people with EGFR-positive, recurrent sinonasal adenoid cystic carcinoma that cannot be surgically removed. The goal is to shrink the …
Matched conditions: SINONASAL ADENOID CYSTIC CARCINOMA
Phase: PHASE2 • Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New chemo approach may spare sinus cancer patients from major surgery
Disease control Recruiting nowThis study is for people with a rare sinus cancer called sinonasal adenoid cystic carcinoma. The treatment delivers high-dose chemotherapy directly to the tumor through a small tube in an artery, aiming to shrink it as much as possible. After three sessions, doctors check if the …
Matched conditions: SINONASAL ADENOID CYSTIC CARCINOMA
Phase: PHASE2 • Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Rare sinus cancer study aims to clarify treatment outcomes
Knowledge-focused Recruiting nowThis study follows people with a rare and advanced cancer of the nasal cavity and sinuses called T4 sinonasal adenoid cystic carcinoma. All participants receive the standard treatment: surgery followed by radiation therapy. The goal is to measure how long people live without the …
Matched conditions: SINONASAL ADENOID CYSTIC CARCINOMA
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC